Connect with us

Health

How Medicaid Cuts Trigger Drop in Weight-Loss Drug Prescriptions

Published

on

How Medicaid Cuts Trigger Drop in Weight-Loss Drug Prescriptions
Share This On:

Thousands of Americans may have lost access to popular weight loss medicines after four states stopped paying for them through Medicaid, a new study suggests. Researchers found that prescriptions fell sharply almost as soon as the coverage changes took effect.

Medicaid is a public health insurance program for people with limited incomes in the United States. It helps many families afford medical care and prescription drugs, but states can choose whether to cover medicines used specifically for weight loss.

On January 1, 2026, California, New Hampshire, Pennsylvania and South Carolina ended Medicaid coverage for certain weight loss drugs known as GLP-1 medicines. These treatments act like a natural hormone that helps control hunger and blood sugar.

ALSO READ:  Seven (7) Surprising Ways Coffee Affects Your Body

Researchers from the University of Pittsburgh examined Medicaid prescription records from every state and Washington, D.C., covering January 2022 through March 2026. Their findings were published on November 16, 2026, in JAMA.

They compared the four states that stopped coverage with 10 states that continued paying for these medicines. In the states that ended coverage, quarterly prescriptions dropped from 2,914 to 421 for every 100,000 Medicaid members between late 2025 and early 2026.

That was an approximately 84% larger decline than the change seen in the comparison states. Pennsylvania experienced the steepest fall, with prescriptions down 95.5%.

ALSO READ:  These Foods Give More Iron And Support Overall Well-being

The researchers estimated that between about 175,500 and 526,600 fewer Medicaid members may have filled prescriptions after the changes. This wide range reflects uncertainty because the records counted prescriptions, not individual patients.

The study also looked for signs that people had switched to similar drugs approved for diabetes. It found no clear increase in those prescriptions in the states that ended weight loss coverage.

This matters because stopping treatment can lead to weight regain for some patients, potentially affecting blood pressure, blood sugar and heart health. However, the study did not follow patients or measure whether their health actually worsened.

ALSO READ:  Types Of Foods That Give More Iron

The findings show a close link between insurance decisions and access to treatment. They cannot prove that every missing prescription was caused by the policy change, since other insurance rules and private purchases were not fully captured.

Even with those limits, the sudden and unusually large drop offers strong evidence that coverage is a major barrier to continuing these medicines. The study highlights why changes in drug benefits deserve careful attention from doctors, patients and policymakers.

Share This On:
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending